Infliximab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Infliximab
- Infliximab: From Crohn's Disease to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
Infliximab: From Crohn's Disease to Colobomatous Microphthalmia-Rhizomelic Dysplasia Syndrome
One-Sentence Summary
Infliximab is a TNF-alpha blocking antibody, originally used for Crohn's disease and other inflammatory conditions such as rheumatoid arthritis, ankylosing spondylitis and ulcerative colitis. The TxGNN model predicts it may be effective for colobomatous microphthalmia-rhizomelic dysplasia syndrome, a rare developmental and skeletal disorder. This prediction is supported by 0 clinical trials and 0 publications, so it rests on the model's graph-based score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Crohn's disease (also inflammatory bowel disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) |
| Predicted New Indication | Colobomatous microphthalmia-rhizomelic dysplasia syndrome |
| TxGNN Prediction Score | 90.22% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 5 |
| Recommended Decision | Hold |
The Singapore licence records compiled for this report carry no approved-indication text. The original indications above come from the TxGNN knowledge graph.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Infliximab is a chimeric monoclonal antibody against TNF-alpha. Its efficacy in Crohn's disease and other immune-mediated inflammatory diseases is well established.
The analysis found no identifiable link between TNF-alpha blockade and this rare developmental and skeletal dysplasia. The condition is a congenital malformation syndrome, not a TNF-driven inflammatory disease. The high TxGNN score (90.22%) is a graph-based prediction only, and no trials or literature support it.
The prediction should therefore be treated as a model output that has not been validated. It is not a credible repurposing lead at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16070P | Remsima Solution for Subcutaneous Injection 120 mg/mL (pre-filled pen) | Injection, solution | — |
| SIN14972P | Remsima Powder for Concentrate for Solution for Infusion 100 mg/vial | Injection, powder, lyophilized, for suspension | — |
| SIN16069P | Remsima Solution for Subcutaneous Injection 120 mg/mL (pre-filled syringe) | Injection, solution | — |
| SIN12120P | Remicade Powder for Concentrate for Solution for Infusion 100 mg/vial | Injection, powder, for solution | — |
| SIN15948P | Ixifi Powder for Concentrate for Solution for Infusion 100 mg/vial | Injection, powder, lyophilized, for solution | — |
All five registrations are valid single-ingredient products, and none is cancelled. All are injectable (intravenous infusion or subcutaneous).
Safety Considerations
- Drug Interactions: The compiled data record 100 interactions. The 20 reviewed here include the following main ones:
- Major:
- Corticosteroids: hydrocortisone, prednisone, prednisolone, dexamethasone, betamethasone, budesonide, triamcinolone (including the ophthalmic form).
- Deferiprone.
- Radiopharmaceuticals: iobenguane (I-131), ibritumomab tiuxetan, tositumomab (I-131).
- Moderate: metronidazole, tinidazole, naltrexone, rosuvastatin, simvastatin.
- Minor: zinc salts (sulfate, acetate, gluconate).
- Major:
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no registered trials, no publications, and no plausible TNF-related mechanism for a congenital developmental and skeletal syndrome. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- A biological or mechanistic rationale linking TNF-alpha signalling to this syndrome, supported by preclinical or genetic data.
- Detailed mechanism of action data for infliximab.
- Package insert warnings and contraindications for the Singapore-registered products, for a safety review.
- Any case reports or preclinical studies in this condition, before reconsidering the decision.
For context, other TxGNN predictions for infliximab are better supported, such as inflammatory spondylopathy (ankylosing spondylitis) and polyarticular juvenile arthritis (both L1). These largely confirm existing or closely related indications rather than representing new repurposing opportunities.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.